Clerk of the House of Representatives
Legislative Resource Center
135 Cannon Building
Washington, DC 20515
http://lobbyingdisclosure.house.gov 		Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510
http://www.senate.gov/lobby
LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Organization/Lobbying Firm Self Employed Individual
American Society of Hematology

2. Address

Address1
2021 L Street NW, Suite 900
 Address2
​
City
WASHINGTON
 State
DC
 Zip Code
20036
 Country
USA

3. Principal place of business (if different than line 2)

City
​
State
​
Zip Code
​
Country
​
4a. Contact Name b. Telephone Number c. E-mail
​Ms.
​Suzanne M. Leous
​2027760544
​sleous@hematology.org
5. Senate ID#
​59171-12
7. Client Name Self Check if client is a state or local government or instrumentality
​American Society of Hematology
6. House ID#
​352060000
TYPE OF REPORT 8. Year
​2023
 Q1 (1/1 - 3/31) Q2 (4/1 - 6/30) Q3 (7/1 - 9/30) Q4 (10/1 - 12/31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report Termination Date
​
11. No Lobbying Issue Activity
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13
12. Lobbying 13. Organizations
INCOME relating to lobbying activities for this reporting period was: EXPENSE relating to lobbying activities for this reporting period were:
Less than $5,000
Less than $5,000
$5,000 or more $
​
$5,000 or more $
​30,000.00
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.
Method A. Reporting amounts using LDA definitions only

Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature
Digitally Signed By: Suzanne M. Leous
 Date
7/20/2023 11:00:01 AM

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

Public health program funding
Federal research funding
Advanced Research Projects Agency for Health (ARPA-H)
FY 2024 NIH funding
FY 2024 AHRQ funding
FY 2024 CDC funding
FY 2024 funding for CDC Sickle Cell Data Collection program
FY 2024 funding for HRSA Sickle Cell Disease Treatment Demonstration program and Sickle Cell Disease Newborn Screening program

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS), Natl Institutes of Health (NIH), Health Resources & Services Administration (HRSA), President of the U.S.

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Tracy
Roades
​
​
Stephanie
Kaplan
​
​
Suzanne
Leous
MPA
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MED

16. Specific lobbying issues

Sickle cell disease/trait issues
Hematology/oncology treatment issues
Hematology/oncology drug research and approval issues
General hematology public health and research issues
Open access policy for peer reviewed research journals
Issues impacting blood supply shortages/safety
Issues impacting delivery of bone marrow, peripheral blood, and cord blood
Clinical trials regulations and coverage
Issues related to diversity, equity, and inclusion (DEI) in hematology research, practice, and training
Advanced Research Projects Agency for Health (ARPA-H)

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), President of the U.S.

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Tracy
Roades
​
​
Suzanne
Leous
MPA
​
Stephanie
Kaplan
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

Coverage of blood transfusions under Medicare Hospice Benefit
Improving Access to Transfusion Care for Hospice Patients Act of 2021 (S. 2186)
Issues related to CAR-T/cellular and gene therapies
Implementation of the Medicare Access and CHIP Reauthorization Act pf 2015 (P.L. 114-10)
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148)
CMS national coverage determinations
Medicaid coverage for sickle cell disease
Issues impacting opioid access/use for patients with hematologic disease and disorders
Issues related to telemedicine/telehealth
Sickle cell disease/trait issues, including coverage for cell and gene therapies
Sickle Cell Disease Comprehensive Care Act (H.R. 1672/S. 996)
Prior authorization
Implementation of the Inflation Reduction Act of 2022 (P.L. 117-169)
Strengthening Medicare for Patients and Providers Act (H.R. 2474)
Resident Physician Shortage Reduction Act (S. 1302)
CONNECT for Health Act (S. 2016/ H.R. 4189)

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA)

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Suzanne
Leous
MPA
​
Tracy
Roades
​
​
Stephanie
Kaplan
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148)
Hematology/oncology drug research and approval issues
Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144)
Clinical trials regulations and coverage
Issues impacting coverage for hematologic diseases and conditions
Issues related to CAR-T/cellular and gene therapies
Issues impacting opioid access/use for patients with hematologic disease and disorders
Issues impacting blood supply shortages/safety
Issues related to diversity, equity, and inclusion (DEI) in hematology research, practice, and training
Implementation of No Surprises Act (P.L. 116-260)
Sickle cell disease/trait issues
Sickle Cell Disease Comprehensive Care Act (H.R. 1672/S. 996)
Issues related to maternal health care and abortion access
Issues related to healthcare workforce
Sickle Cell Care Expansion Act (S. 1423 / H.R. 3100)
Life Saving Leave Act (H.R. 3024)
Cancer Drug Parity Act (S. 2039)
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act (S. 1852/H.R. 3884)
Issues impacting drug shortages

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Natl Institutes of Health (NIH), Centers For Medicare and Medicaid Services (CMS), Centers For Disease Control & Prevention (CDC)

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Suzanne
Leous
MPA
​
Tracy
Roades
​
​
Stephanie
Kaplan
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address
​
City
​
State
​
Zip Code
​
Country
​

21. Client new principal place of business (if different than line 20)

City
​
State
​
Zip Code
​
Country
​

22. New General description of client’s business or activities

​

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name
Last Name
Suffix
First Name
Last Name
Suffix
1
​
​
​
3
​
​
​
2
​
​
​
4
​
​
​

ISSUE UPDATE

24. General lobbying issue that no longer pertains

​
​
​
​
​
​
​
​
​

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

Name Address Principal Place of Business
(city and state or country)
Street Address
City State/Province Zip Country
City
State Country

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

1 2 3

FOREIGN ENTITIES

27. Add the following foreign entities:

Name Address Principal place of business
(city and state or country) 		Amount of contribution for lobbying activities Ownership percentage in client
Street Address
City State/Province Country
City
State Country
%

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

1 3 5
2 4 6

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

Lobbyist Name Description of Offense(s)